Colby Pharmaceutical Company is a privately held clinical drug development company developing both biologic and small molecule drugs for inflammation, pain, and cancer. Colby's lead clinical small molecule and biologic drugs were all selected for their minimal toxicities and side effects as new molecular entities with unique mechanisms of action and are within newly discovered pathways for molecularly targeted therapies to treat or cure patients.
read more »
Disclaimer and Forward-Looking Statements
This web site contains "forward-looking statements," including statements about the Company's growth, future operating results, discovery and development of products, strategic alliances and intellectual property.Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, compensation arrangements, financing needs, plans or intentions relating to acquisitions, business trends and other information that is not historical information. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery, pre-clinical and clinical development programs; failure to obtain grants; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; difficulties or delays in obtaining regulatory approvals to market products and services resulting from the Company's development efforts; product withdrawals; competitive factors; difficulties or delays in commercialization of Company's products; and the requirement for substantial funding to conduct research and development and to expand commercialization activities.